𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Loss of heterozygosity of the L-myc oncogene in human breast tumors

✍ Scribed by Ivan Bieche; Marie-Helene Champeme; Giorgio Merlo; Christian-Jacques Larsen; Robert Callahan; Rosette Lidereau


Publisher
Springer
Year
1990
Tongue
English
Weight
622 KB
Volume
85
Category
Article
ISSN
0340-6717

No coin nor oath required. For personal study only.

✦ Synopsis


Recent studies suggest that loss of heterozygosity may play an important role in various human neoplasia. Cytogenetic abnormalities detected in primary breast tumors led us to examine breast tumor DNAs for deletions. In the present study, we demonstrate, using restriction fragment length polymorphism (RFLP) analysis at the L-myc proto-oncogene (chromosome 1p32), a frequent loss of heterozygosity in primary breast tumor DNAs (55 out of 152 informative tumor DNAs). Most of these deletions appear to be limited to chromosome 1p. No correlation was observed between this genetic alteration and several parameters of each patient's history or characteristics of the tumor. However, a significantly (P = 0.011) shorter survival period after relapse was observed for patients with loss of heterozygosity at L-myc in primary tumor DNAs compared with patients with tumor DNAs lacking this alteration.


📜 SIMILAR VOLUMES


Definition of regions of the human genom
✍ Robert Callahan; Craig Cropp; Zong Mei Sheng; Giorgio Merlo; Patricia Steeg; Dan 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

We have undertaken a systematic study of primary human breast tumor DNA to identify and characterize frequently occurring somatic mutations. Loss of heterozygosity (LOH) has been the most frequent mutation in our panels of primary breast tumor DNA. It is currently thought that LOH reveals recessive

Loss of heterozygosity on the X chromoso
✍ Marie-Louise Loupart; Susan Adams; John A. L. Armour; Rosemary Walker; William B 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 922 KB

The analysis of loss of heterozygosity (LOH) in tumours can be a powerful tool for mapping the sites of tumour suppressor genes in the human genome. A panel of breast cancer patients was assembled as pairs of tumour and lymphocyte DNA samples and LOH studies carried out by Southern hybridisation wit

Expression and loss of heterozygosity of
✍ Dr. Janos Nagy; James S. Clark; Alexander Cooke; Ailsa M. Campbell; James M. Con 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

## Abstract The c‐met proto‐oncogene encodes the receptor to hepatocyte growth factor‐scatter factor (HGF‐SF), a mesenchyme‐derived cytokine with cell‐dissociating, invasion, and angiogenic properties. The expression of c‐met in breast cancer is the subject of controversy; 111 primary breast cancer

Loss of heterozygosity studies in tumors
✍ Moraima Zelada-Hedman; Marta Torroella; Roberto Mesquita; Magnus Nordenskjöld; L 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 488 KB

A gene (BRCA1) predisposing for familial breast and ovarian cancer has been mapped to chromosome band 17q12-21. Based on the observation that ovarian tumors from families with breast and ovarian cancer lose the wild-type allele in the region for the BRCA1 locus, it has been suggested that the gene f

DNA discontinuities in the domain of amp
✍ Néstor O. Bianchi; Dr. Martha S. Bianchi; Juha Kere 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 1022 KB

## Abstract COLO320DM and COLO320HSR are cell lines derived from a human colon carcinoma, Both lines have an amplification of the __MYC__ oncogene: COLO320DM in the form of double minute chromosomes, COLO320HSR as a large marker chromosome with homogeneously staining regions. We have used pulsed fi